85/100 · Critical
Manufactured by Walgreens
Sennosides show a high rate of serious adverse events, with fatigue, nausea, and constipation being common.
63,866 FDA adverse event reports analyzed
Sennosides has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 63,866 adverse event reports for this medication, which is primarily manufactured by Walgreens.
The most commonly reported adverse events include Fatigue, Nausea, Constipation. Of classified reports, 83.7% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. A significant proportion of reported events are serious (83.7%), indicating potential for severe outcomes.
Commonly reported reactions include fatigue, nausea, constipation, and dyspnea, suggesting systemic effects. The data includes serious events like death, pneumonia, and acute kidney injury, warranting careful monitoring.
Patients taking Sennosides should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. No specific drug interactions are detailed in this dataset. However, caution is advised with other medications that may affect bowel function or hydration. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Sennosides received a safety concern score of 85/100 (high concern). This is based on a 83.7% serious event ratio across 28,536 classified reports. The score accounts for 63,866 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 14,499, Male: 12,304, Unknown: 43. The most frequently reported age groups are age 65 (625 reports), age 64 (589 reports), age 75 (585 reports). These demographics reflect reporting patterns and may not represent the full patient population.
No specific drug interactions are detailed in this dataset. However, caution is advised with other medications that may affect bowel function or hydration.
If you are taking Sennosides, here are important things to know. The most commonly reported side effects include fatigue, nausea, constipation, dyspnoea, death. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Discuss any new or worsening symptoms with your doctor, especially if you experience severe fatigue, breathing difficulties, or signs of kidney problems. Ensure adequate hydration while taking sennosides to minimize the risk of dehydration and related complications. Report any unexpected or severe reactions to the FDA to contribute to ongoing safety monitoring. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Sennosides are commonly used laxatives. The high number of serious adverse events, particularly in older age groups, may prompt regulatory review for appropriate use and risk management.
The FDA has received approximately 63,866 adverse event reports associated with Sennosides. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Sennosides include Fatigue, Nausea, Constipation, Dyspnoea, Death. By volume, the top reported reactions are: Fatigue (2,082 reports), Nausea (1,940 reports), Constipation (1,863 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Sennosides.
Out of 28,536 classified reports, 23,874 (83.7%) were classified as serious and 4,662 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Sennosides break down by patient sex as follows: Female: 14,499, Male: 12,304, Unknown: 43. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Sennosides adverse events are: age 65: 625 reports, age 64: 589 reports, age 75: 585 reports, age 72: 565 reports, age 76: 545 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Sennosides adverse event reports is Walgreens. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Sennosides include: Diarrhoea, Pain, Pyrexia, Headache, Pneumonia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Sennosides to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Sennosides has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. A significant proportion of reported events are serious (83.7%), indicating potential for severe outcomes.
Key safety signals identified in Sennosides's adverse event data include: DEATH. PNEUMONIA. ACUTE KIDNEY INJURY. DYSPNOEA. FATIGUE. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
No specific drug interactions are detailed in this dataset. However, caution is advised with other medications that may affect bowel function or hydration. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Sennosides.
Discuss any new or worsening symptoms with your doctor, especially if you experience severe fatigue, breathing difficulties, or signs of kidney problems. Ensure adequate hydration while taking sennosides to minimize the risk of dehydration and related complications. Report any unexpected or severe reactions to the FDA to contribute to ongoing safety monitoring.
Sennosides has 63,866 adverse event reports on file with the FDA. Commonly reported reactions include fatigue, nausea, constipation, and dyspnea, suggesting systemic effects. The volume of reports for Sennosides reflects both the drug's usage level and the vigilance of the reporting community.
Sennosides are commonly used laxatives. The high number of serious adverse events, particularly in older age groups, may prompt regulatory review for appropriate use and risk management. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.